Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Study of LY3016859 in Participants With Diabetic Nephropathy

ClinicalTrials.gov ID: NCT01774981

Public ClinicalTrials.gov record NCT01774981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this two-part study is to investigate the safety, tolerability and efficacy of LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy (DN). Part A will be dose escalation for safety and tolerability and Part B will evaluate Proteinuria.

Study identification

NCT ID
NCT01774981
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2013 (Type not available)
Primary completion
Aug 2015 (Actual)
Completion
Aug 2015 (Actual)
Last update posted
Sep 19, 2019

2013 – 2015

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Innovative Research of West Florida Clearwater Florida 33756 —
Creighton University Medical Center Omaha Nebraska 68131 —
Northeast Clinical Research Center Bethlehem Pennsylvania 18017 —
Southeast Renal Research Institute Chattanooga Tennessee 37408 —
TAD Clinical Research Lufkin Texas 75904 —
Renal Associates, PA San Antonio Texas 78215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01774981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 19, 2019 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01774981 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →